Gritstone Bio Profit Margin

Gritstone Bio (GRTS) currently reports a profit margin of -7825.47% as of June 2024. That compares with -1586.67% in the prior-year period — down 393.2% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Gritstone Bio's profit margin history and peer comparisons.

Gritstone Bio's profit margin decreased from -1586.67% to -7825.47% — a 393.2% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gritstone Bio's profit margin of -7825.47% is lower than the Healthcare sector average of 13.89%. That is roughly 56426.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Gritstone Bio's current -7825.47% should be judged against Healthcare norms (sector average: 13.89%) and against GRTS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -7825.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Gritstone Bio, and consider following GRTS for alerts when major investors trade the stock.